FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide
16.2.2023 11:00:00 EET | Business Wire | Press release
Leading supply chain visibility company FourKites and RCS Logistics, one of the world’s leading independent logistics service providers, today announced a partnership to provide RCS customers with a one-stop shop for end-to-end visibility into their shipments across ocean, air, drayage, intermodal and over-the-road (OTR). Leveraging FourKites’ industry-leading real-time supply chain data, RCS’s internal teams and customers are benefiting from automated, real-time visibility into the status and location of shipments in transit and at rest, all over the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005067/en/
FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide (Photo: Business Wire)
“FourKites’ supply chain visibility platform is a game-changer for RCS Logistics,” says Brian Heaney, President at RCS Logistics. “By providing comprehensive end-to-end visibility data, the industry’s most accurate predictive ETAs and real-time status into shipments, our internal teams are much more efficient and able to focus on higher-value services, while our customers and partners receive a holistic view of their supply chain and shipments. It’s a modern, world-class experience that every stakeholder — large and small — can now enjoy.”
Since deploying the FourKites platform — including the company’s Dynamic Ocean ® solution — in Q3 2022 to track ocean, drayage and OTR shipments, RCS has achieved 7x growth in its domestic transport services, while its ocean freight business has grown 12x. “We are known in the industry as a leading air freight forwarder,” notes Brian Aldridge, SVP Sales, at RCS. “With FourKites, we’ve been able to elevate our ocean freight experience, and connect the dots with other modes, to truly differentiate ourselves in the market. Our customers and partners appreciate FourKites’ simple, modern interface, and the transparency it creates across their supply chain.”
With FourKites in place, track-and-trace teams, drayage providers and warehouse staff have been alleviated of time-consuming manual tracking processes. Moreover, RCS’s data analysts are leveraging FourKites’ advanced analytics — which provide insights into on-time performance, dwell and detention costs, tracking quality, lane and mode performance, and more — to drive continuous improvements in every aspect of the company’s operations.
“We are thrilled to partner with a leader like RCS Logistics, which shares our vision for automated, interconnected and collaborative digital global supply chains, end to end,” says Brad Klaus, Group Vice President, International Solutions, at FourKites. “Our work together illustrates how we integrate across the supply chain ecosystem to modernise operations and provide a superior customer experience in the process.”
Building on the success it has seen to date with ocean, drayage and OTR shipment visibility, the two companies are now working to bring greater visibility to RCS Logistics’ leading door-to-door international air freight forwarding solutions.
About RCS Logistics
RCS Logistics is one of the world’s leading logistics providers specializing in international air, ocean and land freight forwarding, supply chain management, 3PL, trucking transportation, distribution, customs brokerage, and other logistics solutions. To learn more, visit http://www.rcslogistics.com/.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005067/en/
Contact information
Scott Johnston
European PR Director FourKites
+31 62 147 8442
sscott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom